TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 21466925

Group type: EXPERIMENTAL
Intervention: Parent training plus incentives (PTI)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Parent training without incentives (PT)
Number of subjects: 47
Study: 18619686

Group type: EXPERIMENTAL
Intervention: BNP group
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study: 17362251

Group type: EXPERIMENTAL
Intervention: House dust mite and grass allergen challenge
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Wheal size
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Allergen-specific immunoglobulin E (IgE)
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Total IgE
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Current wheeze
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Persistent eczema
Number of subjects: 37
Study: 14769081

Group type: EXPERIMENTAL
Intervention: 30% North African (or 30% Asian) faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 70% North African (or 70% Asian) faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Extremely ambiguous (50%) faces
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mixed-race continua
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: High levels of confidence
Number of subjects: 0
Study: 12577374

Group type: EXPERIMENTAL
Intervention: Puerarin
Number of subjects: 59

Group type: COMPARATOR
Intervention: Ticlid (Control)
Number of subjects: 59
Study: 9502344

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (10 mg)
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 7914736

Group type: EXPERIMENTAL
Intervention: Propofol combined with epidural block with bupivacaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Propofol combined with alfentanil infusions
Number of subjects: 20
Study: 3260967

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate (ISDN)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 31971861

Group type: EXPERIMENTAL
Intervention: Gut microbiome (GM) biomarkers identified from CRC patients
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Classifier based on identified biomarkers
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Quantitative PCR for measuring biomarkers
Number of subjects: 107
Study: 31272926

Group type: EXPERIMENTAL
Intervention: SNr stimulation
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: STN stimulation
Number of subjects: 14

Group type: COMPARATOR
Intervention: Off stimulation
Number of subjects: 14
Study: 28241699

Group type: EXPERIMENTAL
Intervention: Ginaton in addition to conventional treatment
Number of subjects: 116

Group type: COMPARATOR
Intervention: Conventional treatment
Number of subjects: 116
Study: 26044447

Group type: EXPERIMENTAL
Intervention: Dia-Fit (web-based cognitive behaviour therapy)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Waiting list group (control)
Number of subjects: 120
Study: 23859675

Group type: EXPERIMENTAL
Intervention: Linezolid
Number of subjects: 323

Group type: COMPARATOR
Intervention: Vancomycin
Number of subjects: 323
Study: 21921152

Group type: EXPERIMENTAL
Intervention: Less Intensive (LI) belatacept regimen
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: More Intensive (MI) belatacept regimen
Number of subjects: 336

Group type: COMPARATOR
Intervention: Cyclosporine
Number of subjects: 336

Group type: EXPERIMENTAL
Intervention: Belatacept (MI and LI)
Number of subjects: 336
Study: 19689077

Group type: EXPERIMENTAL
Intervention: Multi-micronutrient supplement
Number of subjects: 275

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 275

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 275
Study: 17079638

Group type: EXPERIMENTAL
Intervention: Oral acetaminophen 30 mg x kg(‐1)
Number of subjects: 124

Group type: EXPERIMENTAL
Intervention: Topical 2% lidocaine
Number of subjects: 124
Study: 15646220

Group type: EXPERIMENTAL
Intervention: 5N HCl followed by 5%NaOCl
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5%NaOCl
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5%NaOCl and sonication
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: 5%NaOCl followed by 5N HCl
Number of subjects: 2

Group type: COMPARATOR
Intervention: Polished specimens
Number of subjects: 2
Study: 11709248

Group type: EXPERIMENTAL
Intervention: Healon (sodium hyaluronate 1%)
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Viscoat (sodium hyaluronate 3%-chondroitin sulfate 4%)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Both Healon and Viscoat
Number of subjects: 50
Study: 9541149

Group type: EXPERIMENTAL
Intervention: Carbamazepine treatment
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study: 8017642

Group type: EXPERIMENTAL
Intervention: 0.6% isoflurane in 66% nitrous oxide (group 2)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 1.2% isoflurane in 66% nitrous oxide (group 4)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 0.6% isoflurane in 66% nitrous oxide (group 1)
Number of subjects: 46

Group type: COMPARATOR
Intervention: 1.2% isoflurane in 66% nitrous oxide (group 3)
Number of subjects: 46
Study: 2601309

Group type: EXPERIMENTAL
Intervention: Language-enriched day care program with parent education component
Number of subjects: 0

Group type: COMPARATOR
Intervention: Parent education program without language-enriched day care
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 0
Study: 5558187

Group type: EXPERIMENTAL
Intervention: Home care by the family doctor
Number of subjects: 1203

Group type: COMPARATOR
Intervention: Hospital treatment initially in an intensive care unit
Number of subjects: 1203
Study: 30980679

Group type: EXPERIMENTAL
Intervention: Motivational interviewing plus psychotherapy
Number of subjects: 60

Group type: COMPARATOR
Intervention: Psychotherapy alone
Number of subjects: 60
Study: 28595611

Group type: EXPERIMENTAL
Intervention: traditional clinic‐based CI therapy
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: therapist‐as‐consultant video game CI therapy
Number of subjects: 224

Group type: EXPERIMENTAL
Intervention: therapist‐as‐consultant video game CI therapy with additional therapist contact via telerehabilitation/video consultation
Number of subjects: 224

Group type: COMPARATOR
Intervention: standard upper extremity rehabilitation
Number of subjects: 224
Study: 27140799

Group type: EXPERIMENTAL
Intervention: Single 100-mg doses of migalastat HCl capsule
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Single 100-mg doses of migalastat HCl capsules with a high-fat meal
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Single 150-mg doses of migalastat HCl capsules with a high-fat or light meal
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: 50-g glucose drink co-administered with migalastat HCl
Number of subjects: 35
Study: 23520339

Group type: EXPERIMENTAL
Intervention: Telehealth intervention (telehealth equipment and monitoring services for 12 months)
Number of subjects: 3230

Group type: COMPARATOR
Intervention: Usual care (standard health and social care)
Number of subjects: 3230
Study: 21535185

Group type: EXPERIMENTAL
Intervention: Whey
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CasPost
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: CasPre
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control
Number of subjects: 24
Study: 18931097

Group type: EXPERIMENTAL
Intervention: Disease-management program
Number of subjects: 0
Study: 16769001

Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam (4/0.5/8 h/i.v.)
Number of subjects: 183

Group type: COMPARATOR
Intervention: Metronidazole (500 mg/i.v./8 h) + Gentamicin (5 mg/kg/i.v./24 h)
Number of subjects: 183
Study: 15577832

Group type: EXPERIMENTAL
Intervention: Cat hair and dander extract containing 0.6 mug of Fel d 1
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cat hair and dander extract containing 3 mug of Fel d 1
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Cat hair and dander extract containing 15 mug of Fel d 1
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study: 15330272

Group type: EXPERIMENTAL
Intervention: Plant sterol esters (1.6g daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plant stanol esters (1.6g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Plant stanol esters (2.6g daily)
Number of subjects: 0
Study: 11121918

Group type: EXPERIMENTAL
Intervention: Synthetic porcine secretin 0.2 microgram/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Synthetic porcine secretin 0.4 microgram/kg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Biologically derived porcine secretin 1 CU/kg
Number of subjects: 12
Study: 8883191

Group type: EXPERIMENTAL
Intervention: Original Ashworth scale
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified Ashworth scale
Number of subjects: 30
Study: 1304205

Group type: EXPERIMENTAL
Intervention: Cross-stitch (double running) suture closure
Number of subjects: 200

Group type: COMPARATOR
Intervention: One-stitch technique
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Both groups (4 weeks post-surgery)
Number of subjects: 200
Study: 4028281

Group type: EXPERIMENTAL
Intervention: Bacampicillin (16 g/die)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Amoxicillin (2 g/die)
Number of subjects: 16
Study: 3280741

Group type: EXPERIMENTAL
Intervention: 5‐FU and FA (folinic acid), 200 mg/m2/d for five consecutive days along with 5‐FU, 370 mg/m2/d for five days
Number of subjects: 130

Group type: COMPARATOR
Intervention: 5‐FU alone
Number of subjects: 130
Study: 31046810

Group type: EXPERIMENTAL
Intervention: 7 days of antibiotic treatment
Number of subjects: 284

Group type: COMPARATOR
Intervention: 14 days of antibiotic treatment
Number of subjects: 284
Study: 28389609

Group type: EXPERIMENTAL
Intervention: Nurse-initiated protocols for management of fever, hyperglycemia, and swallowing dysfunction
Number of subjects: 1076

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 1076
Study: 25463962

Group type: EXPERIMENTAL
Intervention: Alcohol dose condition (BAC .05 or .08)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo control group
Number of subjects: 44
Study: 23850630

Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy (CBT) program
Number of subjects: 67
Study: 21726496

Group type: EXPERIMENTAL
Intervention: oral ROF 500 μg q.d. on Days 6 - 10 in addition to oral THEO 375 mg b.i.d. on Days 1 - 10
Number of subjects: 24

Group type: COMPARATOR
Intervention: oral ROF 500 μg q.d. on Days 1 - 5
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: oral THEO 375 mg b.i.d. on Days 1 - 10
Number of subjects: 24
Study: 19417675

Group type: EXPERIMENTAL
Intervention: GlideScope
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Trachlight
Number of subjects: 60

Group type: COMPARATOR
Intervention: Direct laryngoscopy
Number of subjects: 60
Study: 17098656

Group type: COMPARATOR
Intervention: SC group (S): 10 mL of 0.25% bupivacaine and 10 mL of 0.9% saline
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: C group: 10 mL of 0.25% bupivacaine (SF and SC)
Number of subjects: 60
Study: 16305006

Group type: EXPERIMENTAL
Intervention: Bleaching with peroxide and light (exact dosage and duration not specified)
Number of subjects: 43

Group type: COMPARATOR
Intervention: Single-site measurement procedure
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Multiple-site measurement procedure
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Tooth whitening procedures
Number of subjects: 43
Study: 11575895

Group type: EXPERIMENTAL
Intervention: Salmeterol, 50 microg x 2 day(-1)
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Salmeterol
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Long-acting bronchodilators (LABD)
Number of subjects: 67
Study: 9772038

Group type: EXPERIMENTAL
Intervention: Loxiglumide (10 mg/kg/h)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 7511552

Group type: EXPERIMENTAL
Intervention: Proton irradiation as monotherapy (15 lesions)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Proton irradiation as combination therapy with Lipiodol-targeted chemotherapy (17 lesions)
Number of subjects: 24
Study: 3403863

Group type: EXPERIMENTAL
Intervention: BN52063 (120 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 31512395

Group type: EXPERIMENTAL
Intervention: Interval training (I-TRA)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Continuous training (C-TRA)
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 35
Study: 28124397

Group type: EXPERIMENTAL
Intervention: Nidotherapy
Number of subjects: 200

Group type: COMPARATOR
Intervention: Enhanced Care Programme Approach (ECPA)
Number of subjects: 200
Study: 25198942

Group type: COMPARATOR
Intervention: Tamsulosin 0.4 mg once daily (Group A)
Number of subjects: 136

Group type: EXPERIMENTAL
Intervention: Silodosin 8 mg once daily (Group B)
Number of subjects: 136
Study: 23594140

Group type: EXPERIMENTAL
Intervention: Chloral hydrate (CH) 50 mg/kg
Number of subjects: 282

Group type: COMPARATOR
Intervention: Hydroxyzine HCL (HH) 1 mg/kg
Number of subjects: 282
Study: 21288233

Group type: EXPERIMENTAL
Intervention: Oral cholecalciferol 2,000 IU daily for 6 months
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 19200116

Group type: EXPERIMENTAL
Intervention: High-oleic genotypes (4896-11-C, 9399-10)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Normal peanuts
Number of subjects: 16
Study: 16784345

Group type: EXPERIMENTAL
Intervention: Manipulation of affirmative action procedures
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus on losses for the White in-group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Focus on gains for the Black out-group or no effect on Whites
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Perceived fairness
Number of subjects: 0
Study: 15218439

Group type: EXPERIMENTAL
Intervention: Topical metronidazole gel
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 0
Study: 11722961

Group type: EXPERIMENTAL
Intervention: Microencapsulated ferrous fumarate (80 mg elemental Fe) plus ascorbic acid (sprinkles group)
Number of subjects: 557

Group type: COMPARATOR
Intervention: Ferrous sulfate drops (40 mg elemental Fe, administered 3 times/d for 2 months) (control group)
Number of subjects: 557

Group type: EXPERIMENTAL
Intervention: Both groups (sprinkles and drops)
Number of subjects: 557
Study: 9465948

Group type: EXPERIMENTAL
Intervention: Guar with iotrolan (11.2 mg iodine/ml)/guar (4 g/l) suspension
Number of subjects: 20

Group type: COMPARATOR
Intervention: Aqueous solutions of pure iotrolan (11.2 mg iodine/ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Meglumine ioxithalamate (12 mg iodine/ml)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Pure iotrolan
Number of subjects: 20
Study: 8192515

Group type: EXPERIMENTAL
Intervention: Albendazole (20 mg/kg/day) + Cimetidine (10 mg/kg/day)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Albendazole (20 mg/kg/day)
Number of subjects: 19
Study: 3669497

Group type: EXPERIMENTAL
Intervention: Arginine HCl, 500 mg/kg
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Arginine HCl, 200 mg/kg
Number of subjects: 14

Group type: COMPARATOR
Intervention: D-glucose infusion
Number of subjects: 14

Group type: COMPARATOR
Intervention: Ammonium chloride with sodium chloride
Number of subjects: 14
Study: 30833349

Group type: EXPERIMENTAL
Intervention: mixed online hemodiafiltration (mOL-HDF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: bicarbonate hemodialysis (BHD)
Number of subjects: 30
Study: 28399098

Group type: EXPERIMENTAL
Intervention: Heart rate variability biofeedback (HRV BF) session to enhance vagal influences on the heart rhythm.
Number of subjects: 150

Group type: COMPARATOR
Intervention: Relaxed resting state (Control group).
Number of subjects: 150
Study: 26109581

Group type: EXPERIMENTAL
Intervention: Enteral infusion of maltodextrins with protein powder (0.14 g proteins · kg⁻¹ · h⁻¹)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Maltodextrins alone (0.25 g · kg⁻¹ · h⁻¹)
Number of subjects: 6
Study: 24267861

Group type: EXPERIMENTAL
Intervention: Educational intervention
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Educational intervention + pop-up reminder
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Pop-up reminder
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Upper RTI, sinusitis, and otitis
Number of subjects: 328
Study: 21279454

Group type: EXPERIMENTAL
Intervention: SMART intervention (single 90 min one-on-one training)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 40
Study: 19643435

Group type: EXPERIMENTAL
Intervention: Echocardiographically directed duration of indomethacin treatment (ECHO); 0.1 mg/kg
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard treatment; 0.1 mg/kg indomethacin, 2 more doses irrespective of echocardiographic findings
Number of subjects: 74
Study: 17906164

Group type: EXPERIMENTAL
Intervention: Verbal domain tasks requiring supervision and coordination
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visuospatial tasks
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Overall cognitive control processes
Number of subjects: 0
Study: 15086643

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Agility training
Number of subjects: 98

Group type: COMPARATOR
Intervention: Stretching (sham) exercises
Number of subjects: 98
Study: 11719727

Group type: COMPARATOR
Intervention: Fluvoxamine at 0 mg/d
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluvoxamine at 25 mg/d
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Fluvoxamine at 75 mg/d
Number of subjects: 9
Study: 9222234

Group type: EXPERIMENTAL
Intervention: Intravenous foscarnet
Number of subjects: 316

Group type: COMPARATOR
Intervention: Intravenous ganciclovir
Number of subjects: 316
Study: 9063814

Group type: EXPERIMENTAL
Intervention: PCR-RFLP assay with a mismatched primer for ALDH2 genotyping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Nested PCR for ADH2 genotyping
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Newly designed primer pair for ADH2 sequence amplification
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: RFLP and SSCP analyses of PCR products with the new primer set
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADH2 and ALDH2 allele frequencies
Number of subjects: 0
Study: 3294978

Group type: EXPERIMENTAL
Intervention: Nifedipine 30 mg/day for 4 weeks
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 29696220

Group type: EXPERIMENTAL
Intervention: Integrated motivational interviewing (MI) and multi-modal exercise intervention (12 weeks, 3 times per week for 1 hour)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Delayed control group (received the same intervention 12 weeks later)
Number of subjects: 68
Study: 26850076

Group type: EXPERIMENTAL
Intervention: Ibutilide (0.25 mg intravenous)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 200

Group type: EXPERIMENTAL
Intervention: Ibutilide
Number of subjects: 200
Study: 24142988

Group type: EXPERIMENTAL
Intervention: Exercise programme (daily stretching exercise and twice-a-week muscle endurance training)
Number of subjects: 567

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 567

Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 567

Group type: COMPARATOR
Intervention: Exercise programme and Control group
Number of subjects: 567
Study: 21826536

Group type: EXPERIMENTAL
Intervention: Family Foundations (FF) program
Number of subjects: 0
Study: 19914702

Group type: EXPERIMENTAL
Intervention: fesoterodine 4 mg
Number of subjects: 358

Group type: EXPERIMENTAL
Intervention: fesoterodine 8 mg
Number of subjects: 358

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 358
Study: 18375074

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin (24 I.U.)
Number of subjects: 10
Study: 16100213

Group type: EXPERIMENTAL
Intervention: Etanercept, 25 mg subcutaneously twice a week
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Etanercept
Number of subjects: 18
Study: 12019049

Group type: EXPERIMENTAL
Intervention: S-adenosylmethionine (SAMe)
Number of subjects: 11
Study: 11501126

Group type: EXPERIMENTAL
Intervention: rhGH (0.2 U.kg‐1 subcutaneously at 8 a.m. each morning for 14 days)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: rhGH
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control (normal saline as placebo)
Number of subjects: 42
Study: 9012305

Group type: EXPERIMENTAL
Intervention: Laryngeal mask airway
Number of subjects: 100
Study: 1579399

Group type: EXPERIMENTAL
Intervention: Acellular diphtheria‐tetanus toxoids‐pertussis (DTP (ADTP))
Number of subjects: 380

Group type: COMPARATOR
Intervention: Whole‐cell DTP (WDTP)
Number of subjects: 380
Study: 4096057

Group type: EXPERIMENTAL
Intervention: Daily training programme during hospital stay
Number of subjects: 27

Group type: COMPARATOR
Intervention: Conventional rest in bed (Control)
Number of subjects: 27
Study: 31377342

Group type: EXPERIMENTAL
Intervention: Oral Immunotherapy (OIT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Postavoidance SU plasma
Number of subjects: 30
Study: 29475784

Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART)
Number of subjects: 4512
Study: 24481541

Group type: EXPERIMENTAL
Intervention: MHTS service intervention package
Number of subjects: 2238
Study: 23190552

Group type: EXPERIMENTAL
Intervention: Evidence-based care pathway interventions for COPD exacerbation; 38 key interventions developed.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Process and outcome indicators; 24 process indicators and 15 outcome indicators developed.
Number of subjects: 0
Study: 21149772

Group type: EXPERIMENTAL
Intervention: Cryotherapy (cryopexy)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Laser photocoagulation (laserpexy)
Number of subjects: 86
Study: 16997421

Group type: EXPERIMENTAL
Intervention: Etomidate
Number of subjects: 214

Group type: COMPARATOR
Intervention: Propofol
Number of subjects: 214